These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19051240)

  • 41. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
    Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
    Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atorvastatin and diabetic vascular complications.
    Yamagishi S; Matsui T; Nakamura K
    Curr Pharm Des; 2006; 12(12):1549-54. PubMed ID: 16611135
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus.
    Wenzel P; Daiber A; Oelze M; Brandt M; Closs E; Xu J; Thum T; Bauersachs J; Ertl G; Zou MH; Förstermann U; Münzel T
    Atherosclerosis; 2008 May; 198(1):65-76. PubMed ID: 18061195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors.
    Chong PH; Seeger JD
    Pharmacotherapy; 1997; 17(6):1157-77. PubMed ID: 9399600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients.
    Lins LC; França CN; Fonseca FA; Barbosa SP; Matos LN; Aguirre AC; Bianco HT; do Amaral JB; Izar MC
    Cell Biochem Biophys; 2014 Sep; 70(1):687-96. PubMed ID: 24777811
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A new approach to the treatment of dyslipidemia].
    Kevelaitiene S; Slapikas R
    Medicina (Kaunas); 2008; 44(5):407-13. PubMed ID: 18541958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Endothelial function in the forearm circulation of patients with the metabolic syndrome--effect of different lipid-lowering regimens.
    Bulut D; Hanefeld C; Bulut-Streich N; Graf C; Mügge A; Spiecker M
    Cardiology; 2005; 104(4):176-80. PubMed ID: 16155389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
    Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of atorvastatin and atorvastatin-ezetimibe combination therapy on androgen production in hyperandrogenic women with elevated cholesterol levels.
    Krysiak R; Okopien B
    Exp Clin Endocrinol Diabetes; 2015 Feb; 123(2):75-9. PubMed ID: 25350347
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study.
    Spadaccio C; Pollari F; Casacalenda A; Alfano G; Genovese J; Covino E; Chello M
    J Cardiovasc Pharmacol; 2010 Jan; 55(1):30-8. PubMed ID: 19834333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells.
    Rupp S; Badorff C; Koyanagi M; Urbich C; Fichtlscherer S; Aicher A; Zeiher AM; Dimmeler S
    Basic Res Cardiol; 2004 Jan; 99(1):61-8. PubMed ID: 14685707
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes.
    Economides PA; Caselli A; Tiani E; Khaodhiar L; Horton ES; Veves A
    J Clin Endocrinol Metab; 2004 Feb; 89(2):740-7. PubMed ID: 14764790
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of atorvastatin on the angiogenic responsiveness of coronary endothelial cells in normal and streptozotocin (STZ) induced diabetic rats.
    Chaudagar KK; Mehta AA
    Can J Physiol Pharmacol; 2014 Apr; 92(4):338-49. PubMed ID: 24708217
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study.
    Mullen MJ; Wright D; Donald AE; Thorne S; Thomson H; Deanfield JE
    J Am Coll Cardiol; 2000 Aug; 36(2):410-6. PubMed ID: 10933350
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. - From the viewpoint of cholesterol metabolism.-.
    Okada K; Kimura K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S
    Circ J; 2011; 75(10):2496-504. PubMed ID: 21817821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
    Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response.
    Boodhwani M; Nakai Y; Voisine P; Feng J; Li J; Mieno S; Ramlawi B; Bianchi C; Laham R; Sellke FW
    Circulation; 2006 Jul; 114(1 Suppl):I402-8. PubMed ID: 16820608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.